Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CTMX SEC filings page on Stock Titan provides access to CytomX Therapeutics, Inc. regulatory documents as filed with the U.S. Securities and Exchange Commission. CytomX is a clinical-stage, oncology-focused biopharmaceutical company whose common stock trades on the Nasdaq Global Select Market under the symbol CTMX. Its filings offer detailed information on financial performance, risk factors, and the status of its development programs based on its PROBODY® therapeutic platform.
Investors can use this page to locate periodic reports and current reports on Form 8-K. For example, the company has filed 8-K reports to furnish quarterly financial results and to describe material events, such as updates on the CX-2051 Phase 1 study in colorectal cancer. These filings may discuss revenue from collaborations, research and development expenses, cash and investments, and other financial metrics, as well as narrative business updates.
The filings also provide context on clinical and safety disclosures. In one 8-K, CytomX reported an update on the CTMX-2051-101 Phase 1 study, including enrollment across multiple dose levels of CX-2051 and a treatment-related adverse event, along with the Safety Review Committee’s support for continued study execution. Such documents help readers understand how the company reports clinical progress and safety oversight in an official regulatory format.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that can help explain complex sections, highlight key points from lengthy reports, and surface items related to topics such as clinical trial status, collaboration revenues, or liquidity. Users interested in CytomX’s oncology pipeline, including varsetatug masetecan/CX-2051 and CX-801, can review the underlying filings alongside these AI-generated insights to form their own view of the company’s disclosures.
Point72 entities and Steven A. Cohen reported a 5.1% passive stake in CytomX Therapeutics (CTMX). The filing shows 8,084,623 shares are beneficially owned jointly by Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen, with shared voting and dispositive power and no sole voting or dispositive power reported. The disclosure states these shares are held through Point72 Associates and that the positions were not acquired to influence control of the company. Ownership totals are reported as of the close of business on June 30, 2025.
Tang Capital Management and related entities report ownership of 11,065,662 shares of CytomX Therapeutics common stock, representing 7.0% of the outstanding class. The filing shows no sole voting or dispositive power; all reported shares are held with shared voting and dispositive power. The percentages are calculated using 157,544,369 shares outstanding per the issuer prospectus. The filers certify the stake is not held to influence control of the company.
On August 13, 2025, CytomX Therapeutics provided an update on its CX-2051 Phase 1 study. Dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, given every three weeks, have each enrolled approximately 20 patients as planned. The company reported a single Grade 5 treatment-related acute kidney injury in a patient with a complex medical history, including a solitary kidney; the event was believed to be secondary to nausea, vomiting and diarrhea and was reported to the FDA on July 18, 2025. The study's Safety Review Committee convened on July 14, 2025 and supported continued study execution and enrollment.
The CTMX-2051-101 study remains ongoing and a Phase 1 data update is expected by Q1 2026. The filing discloses enrollment progress, the serious adverse event and regulatory reporting but does not provide additional efficacy or broader safety data.
CytomX Therapeutics (CTMX) filed a Form S-8 on 7 Aug 2025 to register 4,381,320 additional common shares for issuance under its Amended & Restated 2015 Equity Incentive Plan. The statement incorporates eleven prior S-8 filings and updates only the exhibit section (legal opinion, auditor consent, revised plan documents).
The company is classified as an accelerated filer and a smaller reporting company. Shares will be issued as option grants, RSUs or other awards vest and are exercised; no immediate cash proceeds are expected. Although the filing does not include financial results, the newly registered shares expand the equity pool, enabling continued employee compensation but creating potential dilution for existing shareholders. All required signatures, powers of attorney and fee calculations are provided.
CytomX Therapeutics (CTMX) Q2-25 10-Q snapshot
Six-month collaboration revenue inched up 4% YoY to $69.6 million, buoyed by Astellas milestones and BMS research fees. Tight cost control (R&D –32% to $32.2 million; G&A flat at $16.1 million) flipped YTD operating loss into a $23.4 million net profit (vs. $7.3 million profit LY), largely from $61.8 million of deferred-revenue recognition tied to Amgen and BMS program terminations. Q2 revenue fell 26% YoY to $18.7 million, producing a modest $0.2 million quarterly loss.
Liquidity strengthened: cash, equivalents and Treasuries rose to $159.5 million (Dec-24: $101.9 million) on a $93.4 million May follow-on offering. Share count is 164.9 million (31 Jul 25). Stockholders’ equity swung to $119.9 million from a $(0.5) million deficit.
- Restructuring: 40 % workforce cut; $3.0 million charges booked.
- Pipeline: CX-2051 showed 28 % ORR (43 % at 10 mg/kg) in Phase 1 colorectal cancer; dose expansions ongoing. CX-801 monotherapy escalation at dose-level 4; Keytruda combo started.
- Collaborations: Amgen EGFR TCE and BMS CTLA-4 licenses ended; remaining deferred revenue $32.3 million expected through 2027.
- Balance-sheet risk: $4.2 million uncertain tax liability from California audit.
Biotechnology Value Fund (BVF) and related entities have filed Amendment No. 5 to Schedule 13G for CytomX Therapeutics, Inc. (CTMX). As of the close of business on 9 July 2025, the group collectively holds 5,769,231 common-share equivalents in the form of Tranche 2 warrants that are exercisable at $3.77 per share and expire on 3 July 2026. The warrants include a 9.99 % beneficial-ownership blocker that limits exercise to keep the holder’s ownership below that threshold.
Beneficial ownership is reported on a disaggregated basis: BVF (3.07 M shares; 1.9 %), BVF II (2.35 M; 1.5 %), and Biotechnology Value Trading Fund OS (0.27 M; <1 %). Through control relationships, BVF GP Holdings and BVF Partners L.P. may be deemed to beneficially own 3.3 % and 3.5 % of outstanding shares, respectively. All entities disclaim ultimate beneficial ownership beyond their respective capacities.
The percentages are calculated against a base of 157.54 M common shares outstanding following the issuer’s May 2025 equity offering, plus the warrants counted as if exercised. No holder exceeds the 5 % reporting threshold individually, and the filing is made on Schedule 13G to reflect passive investment intent; the certification confirms the securities were not acquired to influence control of CTMX.
Key takeaways for investors
- BVF remains a notable but non-controlling holder with a ~3.5 % aggregate economic interest.
- Exposure is entirely via $3.77 warrants, providing potential upside without current voting power.
- The 9.99 % blocker limits near-term ownership expansion but allows full exercise should total shares outstanding rise.
- The amendment updates ownership levels following the issuer’s recent public offering and does not signal activism.